Alaunos Therapeutics (TCRT) Competitors $1.76 -0.04 (-1.94%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TCRT vs. TSBX, BLRX, JAGX, MBIO, EYEN, AWH, PMCB, PHXM, AYTU, and BCDAShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Turnstone Biologics (TSBX), BioLineRx (BLRX), Jaguar Health (JAGX), Mustang Bio (MBIO), Eyenovia (EYEN), Aspira Women's Health (AWH), PharmaCyte Biotech (PMCB), PHAXIAM Therapeutics (PHXM), Aytu BioPharma (AYTU), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Turnstone Biologics BioLineRx Jaguar Health Mustang Bio Eyenovia Aspira Women's Health PharmaCyte Biotech PHAXIAM Therapeutics Aytu BioPharma BioCardia Alaunos Therapeutics (NASDAQ:TCRT) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Is TCRT or TSBX more profitable? Turnstone Biologics' return on equity of -105.99% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -267.77% -209.18% Turnstone Biologics N/A -105.99%-87.27% Which has more risk and volatility, TCRT or TSBX? Alaunos Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Which has preferable valuation and earnings, TCRT or TSBX? Alaunos Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos TherapeuticsN/AN/A-$35.14MN/AN/ATurnstone Biologics$19.31M0.54-$55.20M-$3.24-0.14 Does the MarketBeat Community believe in TCRT or TSBX? Alaunos Therapeutics received 3 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 58.33% of users gave Alaunos Therapeutics an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote. CompanyUnderperformOutperformAlaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Turnstone BiologicsOutperform Votes450.00% Underperform Votes450.00% Do analysts prefer TCRT or TSBX? Turnstone Biologics has a consensus price target of $2.13, indicating a potential upside of 372.22%. Given Turnstone Biologics' stronger consensus rating and higher probable upside, analysts plainly believe Turnstone Biologics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Turnstone Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to TCRT or TSBX? In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Turnstone Biologics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alaunos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turnstone Biologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in TCRT or TSBX? 27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are held by institutional investors. 5.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 32.1% of Turnstone Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryTurnstone Biologics beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.93M$6.55B$5.37B$9.09BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.4686.7617.45Price / SalesN/A318.651,278.6077.80Price / CashN/A22.6336.6032.90Price / Book0.475.034.924.62Net Income-$35.14M$154.90M$117.96M$224.76M7 Day Performance1.10%2.08%2.19%2.84%1 Month Performance-6.63%1.07%3.21%4.81%1 Year Performance-89.68%4.19%26.71%21.17% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics0.1245 of 5 stars$1.77-1.9%N/A-90.0%$2.82MN/A0.0040Gap UpTSBXTurnstone Biologics3.0592 of 5 stars$0.48-0.2%$2.13+343.6%-77.0%$11.08M$19.31M-0.1582News CoverageBLRXBioLineRx2.9691 of 5 stars$0.14-3.8%$9.00+6,450.2%-92.5%$10.98M$21.99M-0.6240Analyst ForecastStock SplitNews CoverageGap UpJAGXJaguar Health0.5596 of 5 stars$0.93-7.4%N/A-86.1%$10.93M$10.48M0.0050MBIOMustang Bio2.6054 of 5 stars$0.22-12.7%$2.00+793.3%-91.8%$10.70MN/A-0.14100Stock SplitGap DownEYENEyenovia2.4598 of 5 stars$0.10-11.1%$2.00+1,983.3%-95.9%$10.70M$31,832.00-0.1340Gap DownAWHAspira Women's Health2.4734 of 5 stars$0.64+1.4%$4.40+587.6%-88.8%$10.67M$8.96M-0.53110Positive NewsGap UpPMCBPharmaCyte BiotechN/A$1.52+0.0%N/A-28.7%$10.59MN/A2.872PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049AYTUAytu BioPharma0.4967 of 5 stars$1.69-2.9%N/A-31.4%$10.39M$79.76M-1.37160Positive NewsBCDABioCardia3.56 of 5 stars$2.25+5.6%$25.00+1,011.1%-66.7%$10.31M$71,000.00-0.5440Positive NewsGap Down Related Companies and Tools Related Companies Turnstone Biologics Alternatives BioLineRx Alternatives Jaguar Health Alternatives Mustang Bio Alternatives Eyenovia Alternatives Aspira Women's Health Alternatives PharmaCyte Biotech Alternatives PHAXIAM Therapeutics Alternatives Aytu BioPharma Alternatives BioCardia Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCRT) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
